Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459875 | 0.87 | FUCA1 (0.56) | FUCA1GBA1GRIN2BS1PR1S1PR5 | |
| SCHEMBL11413096 | 0.85 | FUCA1 (0.60) | FUCA1ALDH1A1GRIN2BS1PR1S1PR5 | |
| SCHEMBL16837173 | 0.83 | FUCA1 (0.58) | FUCA1GRIN2BSIGMAR1DRD2DRD3 | |
| SCHEMBL4191012 | 0.83 | FUCA1 (0.50) | FUCA1ALDH1A1SIGMAR1DRD2DRD3 | |
| SCHEMBL12371118 | 0.82 | FUCA1 (0.68) | FUCA1GBA1ALDH1A1GRIN2BS1PR1 | |
| SCHEMBL3335710 | 0.82 | FUCA1 (0.58) | FUCA1GBA1ALDH1A1S1PR1S1PR5 | |
| SCHEMBL1707693 | 0.82 | FUCA1 (0.68) | FUCA1GBA1ALDH1A1GRIN2BS1PR1 | |
| SCHEMBL15477204 | 0.82 | FUCA1 (0.58) | FUCA1GBA1ALDH1A1S1PR1S1PR5 | |
| SCHEMBL1010709 | 0.82 | FUCA1 (0.58) | FUCA1GBA1ALDH1A1S1PR1S1PR5 | |
| SCHEMBL1707725 | 0.82 | FUCA1 (0.68) | FUCA1GBA1ALDH1A1GRIN2BS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907095-B2 | Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119 | MERCK SHARP & DOHME CORP. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| WO-2008117229-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | FUCA1 1256/4885GBA1 1834/4885ALDH1A1 1806/4885 |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | GPR119, GPR88, GPR180 | FUCA1 3835/4885GBA1 1419/4885ALDH1A1 1771/4885 |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | FUCA1 1335/4885GBA1 1693/4885ALDH1A1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.